ReviewLife (Basel, Switzerland)2021
Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials.Annals of medicine · 2022Pooled it
- FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.Clinical drug investigation · 2022Trial
- Repurposing of colchicine: critical examination of clinical trials and scoping review.European journal of clinical pharmacology · 2026Article
- Differential activation of programmed cell death in patients with severe SARS-CoV-2 infection.Cell death discovery · 2023Article
- The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report.Life (Basel, Switzerland) · 2023Review
- Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses.Heliyon · 2023Review
- Colchicine and macrolides: a cohort study of the risk of adverse outcomes associated with concomitant exposure.Rheumatology international · 2022Article
- Article
- An intra-cytoplasmic route for SARS-CoV-2 transmission unveiled by Helium-ion microscopy.Scientific reports · 2022Article
- Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.Cellular and molecular life sciences : CMLS · 2022Review
- Review
- Appendicitis as a Leading Manifestation of Kawasaki Disease in Older Children.Children (Basel, Switzerland) · 2022Article
- Pyroptotic cell death in SARS-CoV-2 infection: revealing its roles during the immunopathogenesis of COVID-19.International journal of biological sciences · 2022Review
- Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity.Frontiers in immunology · 2022Article
- Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammationTurkish journal of medical sciences · 2021Review
- Colchicine treatment in COVID-19: the remaining unsolved question.The Lancet. Respiratory medicine · 2021Article
- Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) had caused huge health losses worldwide. Several drugs had been applied to treat patients with COVID-19, and repurposing colchicine had been proposed for its anti-inflammatory properties via several pathways. In this systematic review, we evaluated the effects of colchicine treatment. From inception to May 31, 2021, databases, including PubMed, EMbase, medRxiv, and Research Square were searched, and 11 studies were enrolled. A total of 17,205 COVID-19 patients with male predominance (62.9%) were analyzed. Patients with colchicine treatment had a significantly lower risk of mortality (odds ratio (OR): 0.57, 95% confidence interval (CI): 0.38-0.87,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.